Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 11/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.36 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463677 | 0.85 | ALDH1A1 (0.42) | ALDH1A1KDM4ELMNAMEN1POLB | |
| SCHEMBL1172247 | 0.85 | ALDH1A1 (0.41) | ALDH1A1LMNAMEN1POLBKMT2A | |
| SCHEMBL4468713 | 0.80 | HTT (0.39) | ALDH1A1KDM4EMEN1NPC1KMT2A | |
| SCHEMBL1171920 | 0.80 | SMN1; SMN2 (0.43) | ALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL1171998 | 0.78 | CYP19A1 (0.35) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL1171769 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL1171710 | 0.76 | HSP90AA1 (0.37) | HSP90AA1HSP90AB1POLB | |
| SCHEMBL1171876 | 0.73 | HTR1A (0.34) | — | |
| SCHEMBL1171716 | 0.71 | MAPT (0.37) | ALDH1A1KDM4EMEN1POLBKMT2A | |
| SCHEMBL1171746 | 0.71 | CTSD (0.32) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| EP-1981856-A2 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | EPHB4, EPHB1, EPHB3 | AGPAT2 3321/4885ALDH1A1 617/4885KDM4E 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.